Digitalising marketing to physicians: what pharma needs to know
European Pharmaceutical Review explores how the pharmaceutical industry could develop its digital marketing and sales strategies to better align with physician expectations and needs.
List view / Grid view
Articles
MEDICRIME – tackling falsified medicines in Europe
In 2014, medicines were stolen from Italian hospitals and resold across Europe. The authors of a new report highlight the flaws in regulations that handed the perpetrators insufficient sanctions and explain why MEDICRIME provides a better regulatory framework.
Increasing awareness will augment the pharmacovigilance market
A growing requirement for drugs to be safe and effective is being driven by public awareness and understanding. Nilesh Londhe discusses why this pharmacovigilance is increasing.
What pharma needs to know about commercial strategy
European Pharmaceutical Review explores commercial strategy with Dr Simone Seiter, Partner and expert at Simon-Kucher & Partner’s Life Sciences division.
Limiting antibiotic manufacturing discharge in Indian wastewater
During the manufacture of antibiotics, residues can contaminate the environment through wastewater, leading to antimicrobial resistance. However, a new government initiative in India aims to prevent this by regulating effluent.
Artificial intelligence in pharma: utilising a valuable resource
The pharmaceutical industry is set to greatly benefit from the use of artificial intelligence (AI), due to its wide range of applications. Sydney Tierney discusses how machine learning can enhance marketing, manufacturing and drug trials.
Exploring data integrity guideline changes moving into 2020
European Pharmaceutical Review explores how a surge in the number of warning letters for data integrity failings have prompted regulators to publish new guidelines.
Re-shaping pharmaceutical transport: global air cargo trends
As environmental consciousness increases, the future of pharmaceutical transport looks uncertain. Dominic Hyde discusses the impacts of these developments on air cargo and freight.
Cryogel: a solid vaccine for liquid tumours
Researchers have developed a solid ‘cryogel’ vaccine that has been successful in combatting acute myeloid leukaemia in mice. How was this new formulation discovered and what potential does it have for cancer patients?
Five of the most recent developments in anti-cancer therapeutics
European Pharmaceutical Review investigates five of the latest cancer drug approvals and clinical trial results.
How will the rise of biosimilars impact biologics?
Once patents expire for biologic medicines, a market opportunity opens up for biosimilars, a cheaper alternative. With more patents due to expire soon, what will the future look like for biologic medicines?
Digital trends and predictions for pharma in 2020
Bridging the gap between information and operational technology will allow pharma to excel this year. Here, the forthcoming digitalisation trends are projected.
How can NMR spectroscopy help protein biopharmaceutical development?
Nuclear magnetic resonance (NMR) spectroscopy is a technique that most have heard of but many avoid, especially when dealing with larger biological macromolecules. Why? The common wisdom is that NMR can be complicated, expensive and involves quantum physics and complex equations. In the fast-paced industrial biopharmaceutical environment there may be…
Blowing the whistle: tackling misconduct in the life sciences sector
A survey by the Internal Investigations Forum has highlighted vast differences in the quantity and quality of complaint reports globally and that companies need to nurture trust to improve internal relations. Here, Gary Giampetruzzi, Thomas Hauser and Jenny Pu provide an analysis of the results, including where there are areas…
Trends in the CDMO industry for 2020
Over the past decade, the pharmaceutical industry has witnessed rapid growth in outsourcing services, driven by various factors including the growth of small molecules, increasing API complexities and the need to optimise costs. Here, Peter DeYoung shares his thoughts on the key trends he expects to see in the contract…
